← 治験一覧に戻る
健康な被験者およびアトピー性皮膚炎患者におけるLY3844583の研究
基本情報
- NCT ID
- NCT05486208
- ステータス
- 中止
- 試験のフェーズ
- 第1相
- 試験タイプ
- 介入
- 目標被験者数
- 102
- 治験依頼者名
- Eli Lilly and Company
概要
The main purpose of this study is to evaluate the safety and tolerability of LY3844583 in healthy participants and participants with atopic dermatitis. The study will also assess how fast LY3844583 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants and participants with atopic dermatitis. The study will be conducted in three parts and each participant will enroll in one part. The study will last up to 88, 116, and 186 days with 10, 13, and 14 visits for each participant in parts A, B, and C, respectively.
対象疾患
HealthyDermatitis, Atopic
介入
LY3844583(DRUG)
Placebo(DRUG)
依頼者（Sponsor）
日本イーライリリー株式会社(INDUSTRY)
実施施設 (2)
P-one clinic
Hachiōji, Tokyo, Japan
医療法人平心会 大阪治験病院
Osaka, Osaka, Japan